The clinical safety of Trintellix (active ingredient vortioxetine) was based on data collected from MDD clinical studies which included more than 6,700 adult patients, of whom 3,460 were treated with Trintellix (5 to 20 mg/day) in short-term placebo-controlled studies of up to 8 weeks in duration.